시장보고서
상품코드
1194870

종양 바이오시밀러 시장 조사 리포트 : 용도별(암 치료 약물, 지지 요법 약물), 최종사용자별, 지역별 - COVID-19, 러시아·우크라이나 분쟁, 고인플레이션의 누적 영향 예측(2023-2030년)

Oncology Biosimilars Market Research Report by Application (Cancer Treatment Drugs and Supportive Care Drugs), End-User, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, High Inflation - Global Forecast 2023-2030

발행일: | 리서치사: 360iResearch LLP | 페이지 정보: 영문 252 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

종양 바이오시밀러 세계 시장 규모는 2022년에 39억 4,367만 달러에 이를 것으로 추정됩니다. 2023년에는 46억 5,176만 달러에 이르고, 2030년까지 연평균 복합 성장률(CAGR) 18.09%의 성장이 전망되어 149억 1,629만 달러에 달할 것으로 예측됩니다.

목차

제1장 서문

제2장 조사 방법

제3장 주요 요약

제4장 시장 개요

제5장 시장 인사이트

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 해결해야 할 과제
  • COVID-19의 누적 영향
  • 러시아 우크라이나 분쟁의 누적 영향
  • 고인플레이션의 누적 영향
  • Porter's Five Forces 분석
    • 신규 진출기업의 위협
    • 대체품의 위협
    • 대체품의 위협
    • 대체품의 위협
    • 산업 경쟁력
  • 밸류체인 및 중요 경로 분석
  • 규제 프레임워크
  • 클라이언트 커스터마이징

제6장 종양 바이오시밀러 시장 : 용도별

  • 암 치료 약물
  • 지지 요법 약물

제7장 종양 바이오시밀러 시장 : 최종사용자별

  • 병원
  • 소매 약국

제8장 아메리카의 종양 바이오시밀러 시장

  • 아르헨티나
  • 브라질
  • 캐나다
  • 멕시코
  • 미국

제9장 아시아태평양의 종양 바이오시밀러 시장

  • 호주
  • 중국
  • 인도
  • 인도네시아
  • 일본
  • 말레이시아
  • 필리핀
  • 싱가포르
  • 한국
  • 대만
  • 태국
  • 베트남

제10장 유럽, 중동 및 아프리카의 종양 바이오시밀러 시장

  • 덴마크
  • 이집트
  • 핀란드
  • 프랑스
  • 독일
  • 이스라엘
  • 이탈리아
  • 네덜란드
  • 나이지리아
  • 노르웨이
  • 폴란드
  • 카타르
  • 러시아
  • 사우디아라비아
  • 남아프리카공화국
  • 스페인
  • 스웨덴
  • 스위스
  • 터키
  • 아랍에미리트(UAE)
  • 영국

제11장 경쟁 구도

  • FPNV 포지셔닝 매트릭스
    • Quadrants
    • 사업 전략
    • 제품 만족도
  • 시장 순위 분석 : 주요 기업별
  • 시장 점유율 분석 : 주요 기업별
  • 제품 포트폴리오 분석 : 주요 기업별
  • 경쟁 시나리오
    • 인수합병(M&A)
    • 계약/협업/파트너십
    • 신제품 발매 및 기능 개선
    • 투자 및 자금조달
    • 수상/표창/확대

제12장 기업 개요

  • Allergan plc
  • Amneal Pharmaceuticals LLC.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • JSC BIOCAD
  • Lupin Limited
  • Mylan N.V.
  • Novartis AG

제13장 부록

LSH 23.02.01

The Global Oncology Biosimilars Market size was estimated at USD 3,943.67 million in 2022 and expected to reach USD 4,651.76 million in 2023, projecting growth at a CAGR of 18.09% to reach USD 14,916.29 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Oncology Biosimilars Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people's lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Oncology Biosimilars Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Oncology Biosimilars Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Oncology Biosimilars Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the Global Oncology Biosimilars Market in order to forecast the revenues and analyze the trends in each of the following sub-markets.

Based on Application, the market is studied across Cancer Treatment Drugs and Supportive Care Drugs.

Based on End-User, the market is studied across Hospitals and Retail Pharmacies.

Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Oncology Biosimilars Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Oncology Biosimilars Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Oncology Biosimilars Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Oncology Biosimilars Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor's strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Oncology Biosimilars Market, including Allergan plc, Amneal Pharmaceuticals LLC., Apotex Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, Endo International plc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, JSC BIOCAD, Lupin Limited, Mylan N.V., and Novartis AG.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Oncology Biosimilars Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oncology Biosimilars Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oncology Biosimilars Market?

4. What is the competitive strategic window for opportunities in the Global Oncology Biosimilars Market?

5. What are the technology trends and regulatory frameworks in the Global Oncology Biosimilars Market?

6. What is the market share of the leading vendors in the Global Oncology Biosimilars Market?

7. What modes and strategic moves are considered suitable for entering the Global Oncology Biosimilars Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid approval by regulatory authorities for commercialization of products
      • 5.1.1.2. Rising incidence of various types of cancers and leukemia
      • 5.1.1.3. Recent innovation in clinical drug development
    • 5.1.2. Restraints
      • 5.1.2.1. High costs involved in the research
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and innovative treatment options
      • 5.1.3.2. Strategic alliances and investment for capacity expansion
    • 5.1.4. Challenges
      • 5.1.4.1. Limited clinical safety and efficacy data
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Cumulative Impact of Russia-Ukraine Conflict
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Threat of Substitutes
    • 5.5.4. Threat of Substitutes
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework
  • 5.8. Client Customization

6. Oncology Biosimilars Market, by Application

  • 6.1. Introduction
  • 6.2. Cancer Treatment Drugs
  • 6.3. Supportive Care Drugs

7. Oncology Biosimilars Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Retail Pharmacies

8. Americas Oncology Biosimilars Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Oncology Biosimilars Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Oncology Biosimilars Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis, By Key Player
  • 11.3. Market Share Analysis, By Key Player
  • 11.4. Product Portfolio Analysis, By Key Player
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. Allergan plc
  • 12.2. Amneal Pharmaceuticals LLC.
  • 12.3. Apotex Inc.
  • 12.4. Aurobindo Pharma Limited
  • 12.5. Bristol-Myers Squibb Company
  • 12.6. Cipla Inc.
  • 12.7. Eli Lilly and Company
  • 12.8. Endo International plc
  • 12.9. F. Hoffmann-La Roche Ltd.
  • 12.10. GlaxoSmithKline plc
  • 12.11. Glenmark Pharmaceuticals Limited
  • 12.12. JSC BIOCAD
  • 12.13. Lupin Limited
  • 12.14. Mylan N.V.
  • 12.15. Novartis AG

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제